BENDEKA is indicated for the treatment of patients with a Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established or a Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Taking BENDEKA

Your doctor will decide the appropriate dose of BENDEKA. As part of the treatment process, BENDEKA is recommended for intravenous infusion over 10 minutes on Days 1 and 2 of a treatment cycle, for 6 or 8 treatment cycles, depending on your condition.

BENDEKA may be given at a doctor’s office, the hospital, or an infusion center. It is given as an intravenous (IV) infusion that goes directly into a vein through a small needle in your arm.

The following 28- and 21-day calendars show which days during each treatment cycle BENDEKA will be given in either CLL or NHL and for how long.

CLL cycle of treatment

  • This calendar shows 1 cycle of treatment for CLL with BENDEKA

  • Each cycle lasts 28 days

  • You will get your infusion on Day 1 and Day 2 of the 28-day cycle

  • This treatment cycle may be repeated up to 6 times

  • This calendar shows 1 cycle of treatment for CLL with BENDEKA

  • Each cycle lasts 28 days

  • You will get your infusion on Day 1 and Day 2 of the 28-day cycle

  • This treatment cycle may be repeated up to 6 times

NHL cycle of treatment

  • This calendar shows 1 cycle of treatment for NHL with BENDEKA

  • Each cycle lasts 21 days

  • You will get your infusion on Day 1 and Day 2 of the 21-day cycle

  • This treatment cycle may be repeated up to 8 times

  • This calendar shows 1 cycle of treatment for NHL with BENDEKA

  • Each cycle lasts 21 days

  • You will get your infusion on Day 1 and Day 2 of the 21-day cycle

  • This treatment cycle may be repeated up to 8 times

Learn how often treatment with BENDEKA is given

You may or may not have already had an infusion with BENDEKA. Use this calendar tool to help you find out how often you’ll be given BENDEKA.

Select the information below to calculate how often you'll get your treatment and to see when other infusions will next occur. Calculate up to 6 infusion dates for CLL or 8 infusion dates for NHL.

  • *What type of cancer do you have?

    *Start of treatment cycle

    Month
    January
    February
    March
    April
    May
    June
    July
    August
    September
    October
    November
    December
    Day
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    Year

    *Pick the number of months you want to see:

    No. of months
    1 month
    2 months
    3 months
    4 months
    5 months
    6 months

    *Required information.

    Talk to your doctor about exact dates for your next infusions. These dates are for information purposes only. Your doctor may change your infusion dates. If your doctor changes your dates, you can change the remaining dates here. You may not need all treatment cycles in a course of BENDEKA.

    • Cycles
    • Day 1
    • Day 2
    •  
    •  
       
    •  
    •  
       
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  

Your dose may change

Not all patients react to medications the same way, so it may be necessary for your doctor to make changes to the dose of BENDEKA to find out what is right for you or even to stop treatment. Changing the dose or delaying treatment may be necessary if you are experiencing side effects. The most important goal is to find the treatment approach that will help you achieve the best results possible. Your doctor may change, delay, or even stop your treatment.

Important Safety Information

BENDEKA is not right for everyone, including patients with a known allergic response to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol.

BENDEKA may cause serious side effects including: low blood cell counts, infections or recurrence of infections, unexpected responses to BENDEKA when placed in your blood, sudden and severe allergic responses, kidney failure due to fast breakdown of cancer cells, other cancers, and leaking of BENDEKA out of your vein and into your surrounding skin. Some of these side effects, such as low blood counts, infections, liver injury, and severe allergic skin responses (when bendamustine HCL was given alone and in combination with other anticancer medications or allopurinol), have caused death.

Tell your doctor if you have any side effects including: rash, facial swelling, or difficulty breathing during or soon after your infusion with BENDEKA injection. These are signs of an allergic reaction. You also should tell your doctor if you have shortness of breath, significant fatigue, bleeding, bruising, fever, or other signs of infection. Also, tell your doctor if you experience nausea, vomiting, diarrhea, loss of appetite, or a yellow skin tone. In addition, your doctor will perform blood tests to see if you have low blood counts. These are lower-than-normal numbers of red blood cells, white blood cells, or platelets.

Some serious side effects may require changes in therapy, such as lowering the amount of BENDEKA given, stopping the use of BENDEKA, or waiting longer than expected between doses of BENDEKA.

BENDEKA may cause fetal harm if taken while pregnant. Women should avoid becoming pregnant or nursing while receiving BENDEKA.

Non–blood-related side effects may occur including: fever, nausea, and vomiting, diarrhea, constipation, loss of appetite, cough, headache, weight loss, difficulty breathing, rash, and mouth irritation.

Blood-related side effects may occur including: low red blood cells (oxygen-carrying cells), low platelets (blood-clotting cells), and decreased number of three different types of white blood cells (infection-fighting cells).

These are not all of the possible side effects of BENDEKA. For more information ask your healthcare provider.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication

BENDEKA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)—efficacy relative to first-line therapies other than chlorambucil has not been established—or indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Please read the Full Prescribing Information.

 

Are you a healthcare professional?

The information on this site is intended for healthcare professsionals
in the United States. Are you a healthcare professional in the United States?

 

Contact us

Medical Information

For healthcare professionals or patients with specific medical questions about BENDEKA®, please contact:

Teva Medical Information

1-888-4-TEVARX (1-888-483-8279)
To request more information about BENDEKA, click here.

 

You are about to leave this site

You are about to leave BENDEKA.com and enter a website operated by a third party.
Would you like to continue?